Thubilux Pharma SpA has received a structured loan of US$2.7 million from a leading Italian bank
Tubilux Pharma SpA has successfully raised funds through a structured loan from Cassa Depositi e Prestiti SpA and Banca Intesa San Paolo SpA to support an investment plan for a new production facility which has all the FDA requirements to enter the USA market.
Tubilux Pharma is a leading, privately-held ophthalmic and pharmaceuticals company that develops and markets a range of proprietary, over-the-counter, and branded generic products, with distribution in approximately 30 countries. The firm's customers are large multinational pharmaceutical companies that outsource their production of ophthalmic products to specialized manufactures through medium-term supply contracts (3-5 years).
Oaklins' team in Italy advised Thubilux Pharma SpA in the structuring, negotiation and closing of a long-term debt financing from a leading Italian bank, backed by Cassa Depositi e Prestiti.
Talk to the deal team
Related deals
Rare Patient Voice has been acquired by Konovo
Rare Patient Voice has been acquired by Konovo, a technology-first healthcare intelligence company backed by Fraser Healthcare Partners.
Learn moreGSP Group has secured an upsized growth refinancing package from HSBC
The GSP Group has refinanced its growth facilities through an upsized financing package provided by HSBC.
Learn moreLindenhofgruppe has sold its majority stake in LabPoint to Affidea Switzerland
LabPoint Medical Laboratories AG has been acquired by Affidea Switzerland AG. Through the transaction, Lindenhofgruppe AG gains a strong strategic partner to support the further development of LabPoint and will remain a shareholder with a reduced stake, continuing as a key customer of the company. It lays the foundation for LabPoint’s sustainable development under a new anchor shareholder, with the aim of further strengthening and selectively expanding its position in laboratory diagnostics.
Learn more